|26.09||-0.3300||-1.25%||Vol 536.85K||1Y Perf 32.98%|
|Apr 9th, 2021 16:00 DELAYED|
|- -||- -%|
|Target Price||37.86||Analyst Rating||Strong Buy 1.09|
|Potential %||45.11||Finscreener Ranking||★★+ 48.95|
|Insiders Trans % 3/6/12 mo.||-100/-100/-97||Value Ranking||★+ 45.06|
|Insiders Value % 3/6/12 mo.||-100/-100/-99||Growth Ranking||★★★ 52.16|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-99||Income Ranking||— -|
|Market Cap||1.99B||Earnings Rating||Strong Sell|
|Price Range Ratio 52W %||71.57||Earnings Date||6th May 2021|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|3/2021 QR||-0.29||-1 350.00||Negative|
|Next Report Date||6th May 2021|
|Estimated EPS Next Report||-0.28|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||532.12K|
|Avg. Monthly Volume||769.97K|
|Avg. Quarterly Volume||828.69K|
Dicerna Pharmaceuticals Inc. (NASDAQ: DRNA) stock closed at 26.09 per share at the end of the most recent trading day (a -1.25% change compared to the prior day closing price) with a volume of 537.00K shares and market capitalization of 1.99B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 302 people. Dicerna Pharmaceuticals Inc. CEO is Douglas M. Fambrough.
The one-year performance of Dicerna Pharmaceuticals Inc. stock is 32.98%, while year-to-date (YTD) performance is 18.43%. DRNA stock has a five-year performance of 393.19%. Its 52-week range is between 16.5 and 29.9, which gives DRNA stock a 52-week price range ratio of 71.57%
Dicerna Pharmaceuticals Inc. currently has a PE ratio of -16.90, a price-to-book (PB) ratio of 14.17, a price-to-sale (PS) ratio of 15.91, a price to cashflow ratio of 10.80, a PEG ratio of 2.32, a ROA of -16.60%, a ROC of -74.27% and a ROE of -74.31%. The company’s profit margin is -69.37%, its EBITDA margin is -86.80%, and its revenue ttm is $130.28 Million , which makes it $1.71 revenue per share.
Of the last four earnings reports from Dicerna Pharmaceuticals Inc., there were 0 positive earnings surprise and 4 negative earnings surprise. The company has EPS estimate of $-0.28 for the next earnings report. Dicerna Pharmaceuticals Inc.’s next earnings report date is 06th May 2021.
The consensus rating of Wall Street analysts for Dicerna Pharmaceuticals Inc. is Strong Buy (1.09), with a target price of $37.86, which is +45.11% compared to the current price. The earnings rating for Dicerna Pharmaceuticals Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Dicerna Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Dicerna Pharmaceuticals Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 11.75, ATR14 : 1.94, CCI20 : 36.32, Chaikin Money Flow : -0.06, MACD : 0.74, Money Flow Index : 57.75, ROC : 1.19, RSI : 55.31, STOCH (14,3) : 58.01, STOCH RSI : 0.37, UO : 54.62, Williams %R : -41.99), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Dicerna Pharmaceuticals Inc. in the last 12-months were: Adam M. Koppel (Sold 1 000 000 shares of value $23 400 000 ), Bob Brown (Option Excercise at a value of $1 175 906), Bob Brown (Sold 277 976 shares of value $6 496 273 ), Douglas M. Fambrough (Buy at a value of $180 597), Douglas M. Fambrough (Option Excercise at a value of $0), James B. Weissman (Option Excercise at a value of $219 070), James B. Weissman (Sold 77 804 shares of value $1 764 768 ), John B. Green (Option Excercise at a value of $139 651), John B. Green (Sold 25 624 shares of value $588 071 ), Regina M. Paglia (Option Excercise at a value of $617 071), Regina M. Paglia (Sold 34 619 shares of value $856 147 ), Robert D. Ciappenelli (Option Excercise at a value of $0)
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.